Syngenta/BioLeap enter research collaboration
Syngenta has entered into a research collaboration with US drug discovery and design company BioLeap (Ewing, New Jersey) to apply BioLeap molecular design technology to the discovery of crop protection products. Syngenta’s venture capital subsidiary, Syngenta Ventures, will make an equity investment in BioLeap, which will provide molecular designs for the synthesis of compounds aimed at targets of interest in crop protection. The agreement builds upon and expands previous research carried out for Syngenta, BioLeap says. Financial details of the agreement have not been disclosed.